Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Efficacy I PLUVICTO
Medicus Economics, LLC on LinkedIn: Real-world treatment patterns and overall survival among men with…
Frontiers | Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
IJMS | Free Full-Text | The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Pluvicto Delays Progression in Earlier mCRPC, but Crossover Muddies Overall Survival Analysis | Precision Medicine Online
Pharmaceutics | Free Full-Text | Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - ScienceDirect
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC - Medical Conferences
Targeted Alpha Therapy Optimising Survival in Advanced Prostate Cancer
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting - European Urology ...
PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape | Published in healthbook TIMES Oncology Hematology
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer - Chung-Shien Lee, So Yi Lam, Angel Liu, Cristina Sison, Xin-Hua Zhu, 2023
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
